Cargando…

Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders

The objective of this study was to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A consecutive sample of patients with a confirmed diagnosis of unipolar (UP n=52) or bipolar depression (BP-I n=46, BP-II n=49) and controls (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Frye, M A, Nassan, M, Jenkins, G D, Kung, S, Veldic, M, Palmer, B A, Feeder, S E, Tye, S J, Choi, D S, Biernacka, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068585/
https://www.ncbi.nlm.nih.gov/pubmed/26645624
http://dx.doi.org/10.1038/tp.2015.185
_version_ 1782460803445686272
author Frye, M A
Nassan, M
Jenkins, G D
Kung, S
Veldic, M
Palmer, B A
Feeder, S E
Tye, S J
Choi, D S
Biernacka, J M
author_facet Frye, M A
Nassan, M
Jenkins, G D
Kung, S
Veldic, M
Palmer, B A
Feeder, S E
Tye, S J
Choi, D S
Biernacka, J M
author_sort Frye, M A
collection PubMed
description The objective of this study was to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A consecutive sample of patients with a confirmed diagnosis of unipolar (UP n=52) or bipolar depression (BP-I n=46, BP-II n=49) and controls (n=141) were recruited. A 7.5-ml blood sample was drawn for proteomic multiplex profiling of 320 proteins utilizing the Myriad RBM Discovery Multi-Analyte Profiling platform. After correcting for multiple testing and adjusting for covariates, growth differentiation factor 15 (GDF-15), hemopexin (HPX), hepsin (HPN), matrix metalloproteinase-7 (MMP-7), retinol-binding protein 4 (RBP-4) and transthyretin (TTR) all showed statistically significant differences among groups. In a series of three post hoc analyses correcting for multiple testing, MMP-7 was significantly different in mood disorder (BP-I+BP-II+UP) vs controls, MMP-7, GDF-15, HPN were significantly different in bipolar cases (BP-I+BP-II) vs controls, and GDF-15, HPX, HPN, RBP-4 and TTR proteins were all significantly different in BP-I vs controls. Good diagnostic accuracy (ROC-AUC⩾0.8) was obtained most notably for GDF-15, RBP-4 and TTR when comparing BP-I vs controls. While based on a small sample not adjusted for medication state, this discovery sample with a conservative method of correction suggests feasibility in using proteomic panels to assist in identifying and distinguishing mood disorders, in particular bipolar I disorder. Replication studies for confirmation, consideration of state vs trait serial assays to delineate proteomic expression of bipolar depression vs previous mania, and utility studies to assess proteomic expression profiling as an advanced decision making tool or companion diagnostic are encouraged.
format Online
Article
Text
id pubmed-5068585
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50685852016-10-20 Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders Frye, M A Nassan, M Jenkins, G D Kung, S Veldic, M Palmer, B A Feeder, S E Tye, S J Choi, D S Biernacka, J M Transl Psychiatry Original Article The objective of this study was to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A consecutive sample of patients with a confirmed diagnosis of unipolar (UP n=52) or bipolar depression (BP-I n=46, BP-II n=49) and controls (n=141) were recruited. A 7.5-ml blood sample was drawn for proteomic multiplex profiling of 320 proteins utilizing the Myriad RBM Discovery Multi-Analyte Profiling platform. After correcting for multiple testing and adjusting for covariates, growth differentiation factor 15 (GDF-15), hemopexin (HPX), hepsin (HPN), matrix metalloproteinase-7 (MMP-7), retinol-binding protein 4 (RBP-4) and transthyretin (TTR) all showed statistically significant differences among groups. In a series of three post hoc analyses correcting for multiple testing, MMP-7 was significantly different in mood disorder (BP-I+BP-II+UP) vs controls, MMP-7, GDF-15, HPN were significantly different in bipolar cases (BP-I+BP-II) vs controls, and GDF-15, HPX, HPN, RBP-4 and TTR proteins were all significantly different in BP-I vs controls. Good diagnostic accuracy (ROC-AUC⩾0.8) was obtained most notably for GDF-15, RBP-4 and TTR when comparing BP-I vs controls. While based on a small sample not adjusted for medication state, this discovery sample with a conservative method of correction suggests feasibility in using proteomic panels to assist in identifying and distinguishing mood disorders, in particular bipolar I disorder. Replication studies for confirmation, consideration of state vs trait serial assays to delineate proteomic expression of bipolar depression vs previous mania, and utility studies to assess proteomic expression profiling as an advanced decision making tool or companion diagnostic are encouraged. Nature Publishing Group 2015-12 2015-12-08 /pmc/articles/PMC5068585/ /pubmed/26645624 http://dx.doi.org/10.1038/tp.2015.185 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Frye, M A
Nassan, M
Jenkins, G D
Kung, S
Veldic, M
Palmer, B A
Feeder, S E
Tye, S J
Choi, D S
Biernacka, J M
Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title_full Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title_fullStr Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title_full_unstemmed Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title_short Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
title_sort feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068585/
https://www.ncbi.nlm.nih.gov/pubmed/26645624
http://dx.doi.org/10.1038/tp.2015.185
work_keys_str_mv AT fryema feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT nassanm feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT jenkinsgd feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT kungs feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT veldicm feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT palmerba feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT feederse feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT tyesj feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT choids feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders
AT biernackajm feasibilityofinvestigatingdifferentialproteomicexpressionindepressionimplicationsforbiomarkerdevelopmentinmooddisorders